New insights into the molecular biology of the glomerular filtration barrier and associated disease

Nephrology

Volumn 10, Issue 2, 2005, Pages 157-166

  Levidiotis, Vicki ^a,b   Power, David A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Endothelial cells; Glomerular basement membrane; Molecular biology; Podocytes; Proteinuria

Indexed keywords

ANATOMY; CHEMISTRY; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; FATALITY; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION; HUMAN; KIDNEY; MEDICAL GENETICS; MOLECULAR BIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANIMALS; BASEMENT MEMBRANE; COLLAGEN TYPE IV; HUMANS; INTEGRINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; LAMININ; PROTEOGLYCANS;

EID: 20144376222     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00385.x     Document Type: Review

References (94)

1. Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. N. Engl. J. Med. 1978; 298: 826-33.
2. Kanwar YS, Liu ZZ, Kashihara N, Wallner EI. Current status of the structural and functional basis of glomerular nitration and proteinuria. Semin. Nephrol. 1991; 11: 390-413.
3. Jorgensen F. Electron microscopic studies of normal glomerular basement membrane. Lab. Invest. 1967; 17: 416-24.
4. Jorgensen F. Electron microscopic studies of normal visceral epithelial cells. Lab. Invest. 1967b; 17: 225-42.
5. Jorgensen F, Bentzon MW. The ultastructure of the normal human glomerulus. Thickness of glomerular basement membrane. Lab. Invest. 1968; 18: 42-8.
6. Laulajainen T, Julkunen I, Haltia A, Knuutila S, Miettinen A, Holthofer H. Establishment and characterization of a rat glomerular endothelial cell line. Lab. Invest. 1993; 69: 183-92.
7. Miettinen A, Dekan G, Farquhar MG. Monoclonal antibodies against membrane proteins of the rat glomerulus. Immunochemical specificity and immunofluorescence distribution of the antigens. Am. J. Pathol. 1990; 137: 929-44.
8. Noakes PG, Miner JH, Gautam M, Cunningham JM, Sanes JR, Merlie JP. The renal glomerulus of mice lacking s-laminin/laminin beta 2: nephrosis despite molecular compensation by laminin beta 1. Nat. Genet. 1995; 10: 400-6.
9. Peissel B, Geng L, Kalluri R et al. Comparative distribution alphal(IV), alpha5(IV), and alpha6(IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients. J. Clin. Invest. 1995; 96: 1948-57.
10. Mochizuki T, Lemmink HH, Mariyama M et al. Identification of mutations in the alpha3(IV) and alpha4(IV) collagen genes in autosomal recessive Alport syndrome. Nat. Genet. 1994; 8: 77-81.
11. Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999; 78: 338-60.
12. Kalluri R, Shield CF, Todd P, Hudson BG, Neilson EG. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J. Clin. Invest. 1997; 99: 2470-78.
13. Hudson BG, Wieslander J, Wisdom BJ Jr, Noelken ME. Goodpasture syndrome: molecular architecture and function of basement membrane antigen. Lab. Invest. 1989; 61: 256-69.
14. Hudson BG, Kalluri R, Gunwar S et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3 (IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int. 1992; 42: 179-87.
15. Gross O, Beirowski B, Harvey SJ et al. DDR 1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney Int. 2004; 66: 102-11.
16. Korhonen M, Ylanne J, Laitinen L, Virtanen I. The alpha 1-alpha 6 subunits of integrins are characteristically expressed in distinct segments of developing and adult human nephron. J. Cell Biol. 1990; 111: 1245-54.
17. Kreidberg JA, Donovan MJ, Goldstein SL et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996; 122: 3537-47.
18. Bataldi A, Zambruno G, Furci L et al. Beta 1 and beta 3 integrin upregulation in rapidly progressive glomerulonephritis. Nephrol. Dial. Transplant. 1995; 10: 1155-61.
19. Reiser J, Oh J, Shirato I et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J. Biol. Chem. 2004; 13: 34 827-32.
20. Mayer U, Nischt R, Poschl E et al. A single EGF-like motif of laminin is responsible for high affinity nidogen binding. EMBO J. 1993; 12: 1879-85.
21. Aumailley M, Wiedemann H, Mann K, Timpl R. Binding of nidogen and the laminin-nidogen complex to basement membrane collagen type IV. Eur. J. Biochem. 1989; 184: 241-8.
22. Groffen AJ, Veerkamp JH, Monnens LA, van den Heuvel LP. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol. Dial. Transplant. 1999; 14: 2119-29.
23. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 2003; 278: 12 605-8.
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl J. Med. 2003; 349: 427-34.
25. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003; 111: 707-16.
26. Nicole S, Davoine CS, Topaloglu H et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet. 2000; 26: 480-83.
27. Arikawa-Hirasawa E, Wilcox WR, Le AH et al. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat. Genet. 2001; 27: 431-4.
28. McCormick C, Leduc Y, Martindale D et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat. Genet. 1998; 19: 158-61.
29. Grisaru S, Rosenblum ND. Glypicans and the biology of renal malformations. Pediatr. Nephrol. 2001; 16: 302-6.
30. Raats CJ, Van Den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int. 2000; 57: 385-400.
31. Termaat RM, Brinkman K, van Compel F et al. Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J. Autoimmun. 1990; 3: 531-45.
32. Kramers C, Hylkema MN, van Bruggen MC et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J. Clin. Invest. 1994; 94: 568-77.
33. Schmiedeke TM, Stockl FW, Weber R, Sugisaki Y, Batsford SR, Vogt A. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J. Exp. Med. 1989; 169: 1879-94.
34. Ghiggeri GM, Bertelli R, Ginevri F et al. Multiple mechanisms for doxorubicin cytotoxicity on glomerular epithelial cells 'in vitro'. Eur J. Pharmacol. 1992; 228: 77-83.
35. Baud L, Hagege J, Sraer J, Rondeau E, Perez J, Ardaillou R. Reactive oxygen production by cultured rat glomerular mesangial cells during phagocytosis is associated with stimulation of lipoxygenase activity. J. Exp. Med. 1983; 158: 1836-52.
36. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J. Clin. Invest. 1986; 11: 762-7.
37. Radeke HH, Meier B, Topley N, Fioge J, Habermehl GG, Resch K. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int. 1990; 37: 767-75.
38. Sedor JR, Carey SW, Emancipator SN. Immune complexes bind to cultured rat glomerular mesangial cells to stimulate superoxide release. Evidence for an Fc receptor. J. Immunol. 1987; 138: 3751-7.
39. Moseley R, Waddington R, Evans P, Halliwell B, Embery G. The chemical modification of glycosaminoglycan structure by oxygen-derived species in vitro. Biochim. Biophys. Acta 1995; 1244: 245-52.
40. Tay M, Comper WD, Vassiliou P, Glasgow EF, Baker MS, Pratt L. The inhibitory action of oxygen radical scavengers on proteinuria and glomerular heparan sulphate loss in the isolated perfused kidney. Biochem. Int. 1990; 20: 767-78.
41. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J. Biol. Chem. 1997; 272: 26 734-41.
42. Hiebert LM, Liu JM. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 1990; 83: 47-51.
43. van Bruggen MC, Walgreen B, Rijke TP et al. Heparin and heparinoids prevent the binding of immune complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int. 1996; 50: 1555-64.
44. Chen ZY, Jiang XY, Fei L. Effect of heparin on the anionic sites of glomerular basement membrane in adriamycin nephrosis in rats. Chin. Med. J. (Engl.) 1992; 105: 671-5.
45. Gambaro G, Venturini AP, Noonan DM et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 1994; 46: 797-806.
46. van den Bom J, van den Heuvel LP, Bakker MA et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int. 1993; 43: 454-63.
47. van den Born J, van Kraats AA, Bakker MA et al. Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy. Diabetologia 1995a; 38: 1169-75.
48. van den Born J, van Kraats AA, Bakker MA et al. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 1995; 38: 161-72.
49. van den Born J, Berden JH. Is microalbuminuria in diabetes due to changes in glomerular heparan sulphate? (Editorial) Nephrol. Dial. Transplant. 1995; 10: 1277-9.
50. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autotadiographic evidence. Proc. Natl Acad. Sci. USA 1983; 80: 2272-7.
51. Levy P, Picard J, Bruel A. Evidence for diabetes-induced alterations in the sulfation of heparin sulfate intestinal epithelial cells. Life Sci. 1984; 35; 2613-20.
52. Yokoyama H, Hoyer PE, Hansen PM et al. Immunohistochemical quantification of heparan sulfate proteoglycan and collagen IV in skeletal muscle capillary basement membranes of patients with diabetic nephropathy. Diabetes 1997; 46: 1875-80.
53. van der Pijl JW, Daha MR, van den Born J et al. Extracellular matrix in human diabetic nephropathy: reduced expression of heparan sulphate in skin basement membrane. Diabetoiogia 1998; 41: 791-8.
54. Levidiotis V, Kanellis J, Ierino FL, Power DA. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int. 2001; 60: 1287-96.
55. Johnson RJ, Couser WG, Alpers CE, Vissers M, Schuhe M, Klebanoff SJ. The human neutrophil serine proteinases, elastase and cathepsin G, can mediate glomerular injury in vivo. J. Exp. Med. 1988; 168: 1169-74.
56. Heeringa P, Van den Born J, Brouwer E et al. Elastase, hut not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after in vivo renal perfusion in rats. Clin. Exp Immunol. 1996; 105: 321-9.
57. Zcharia E, Metzger S, Chajek-Shaul T et al. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J. 2004; 18: 252-63.
58. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J. Am. Soc. Nephrol. 2004; 15: 68-78.
59. Levidiotis V, Freeman C, Punler M et al. A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J. Am. Soc. Nephrol. 2004; 15: 2882-92.
60. Harper JW, Adams PD. Cyclin-dependent kinases. Chem. Rev. 2001; 101: 2511-26.
61. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13: 1501-12.
62. Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays 1998; 20: 1020-29.
63. Tomari S, Nagahama H, Shu Y et al. Glomerular differentiation in p27 and p57 double-mutant metanephrol. Anat. Embryol. 2002; 206: 31-6.
64. Shankland SJ, Floege J, Thomas SE et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int. 1997; 52: 404-13.
65. Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ. DNA damage is is a novel response to sublytic complement C5b-9-induced injury in podocytes. J. Clin. Invest. 2003; 111: 877-85.
66. Nelson PJ, Gelman IH, Klotman PE. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J. Am. Soc. Nephrol. 2001; 12: 2827-31.
67. Petermann AT, Hiromura K, Blonski M et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int. 2002; 61: 40-50.
68. Endlich K, Kriz W, Witzgall R. Update in podocyte biology. Curr. Opin. Nephrol. Hypertens. 2001; 10: 331-40.
69. Harrison-Bernard LM, Navar LO, Ho MM, Vinson GP, el-Dahr SS. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am. J. Physiol. 1997; 273: F170-77.
70. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334; 939-45.
71. Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol. Dial. Transplant. 1996; 11: 1003-11.
72. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992; 68: 283-302.
73. Denker BM, Nigatn SK. Molecular structure and assembly of the tight junction. Am. J. Physiol. 1998; 274: F1-9.
74. Holthofer H, Ahola H, Solin ML et al. Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am. J. Pathol. 1999; 155: 1681-7.
75. Ruotsalainen V, Patrakka J, Tissari P et al. Role of nephrin in cell junction formation in human nephrogenesis. Am. J. Pathol. 2000; 157: 1905-16.
76. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J. Am. Soc. Nephrol. 2000; 11: 1-8.
77. Scott MP, Tamkun JW, Hartzell GW III. The structure and function of the homeodomain. Biochim. Biophys. Acta 1989; 989: 25-48.
78. Mugrauer G, Ekblom P. Contrasting expression patterns of three members of the myc family of protooncogenes in the developing and adult mouse kidney. J. Cell Biol 1991; 112: 13-25.
79. Matsui K, Breiteneder-Geleff S, Kerjaschki D. Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause ptoteinuria and rapid flattening of podocytes. J. Am. Soc. Nephrol. 1998; 9: 2013-26.
80. Debiec H, Nauta J, Coulet F et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364: 1252-9.
81. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 1999; 10: 51-61.
82. Shirato I, Sakai T, Kimura K, Tomino Y, Kriz W. Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis. Am. J. Pathol. 1996; 148: 1283-96.
83. Smoyer WE, Mundel P, Gupta A, Welsh MJ. Podocyte alpha-actinin induction precedes foot process effacement in experimental nephrotic syndrome. Am. J. Physiol. 1997; 273: F150-57.
84. Sonnenberg E, Godecke A, Walter B, Bladt F, Birchmeier C. Transient and locally restricted expression of the rosl protooncogene during mouse development. EMBO J. 1991; 10: 3693-702.
85. Wolf G, Stahl RA. CD2-associated protein and glomerular disease. Lancet 2003; 362: 1746-8.
86. Kim JM, Wu H, Green G et al. CD2-associated protein haploin-sufficiency is linked to glomerular disease susceptibility. Science 2003; 300: 1298-300.
87. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum. Mol. Genet. 2001; 10: 18.
88. Topham PS, Kawachi H, Haydar SA et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J. Clin. Invest. 1999; 104: 1559-66.
89. Benigni A, Tomasoni S, Gagliardini E et al. Blocking angiotensin 11 synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J. Am. Soc. Nephrol. 2001; 12: 941-8.
90. Schaefer L, Ren S, Schaefer RM et al. Nephrin expression is increased in anti-Thy1.1-induced glomerulonephritis in rats. Biochem. Biophys. Res. Commun. 2004; 324: 247-54.
91. Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am. J. Pathol. 2001; 158: 1723-31.
92. Patrakka J, Ruotsalainen V, Reponen P et al. Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. Transplantation 2002; 73: 394-403.
93. Roselli S, Gribouval O, Boute N et al. Podocin localizes in the kidney to the slit diaphragm area. Am. J. Pathol. 2002; 160: 131-9.
94. Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet. 2000; 24: 251-6.